AFFiRiS AG-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:AFFiRiS AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011786
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Affiris AG (AFFiRiS) is a drug development company that develops and manufactures novel synthetic vaccines against chronic diseases. The company develops customized peptide vaccines based on its proprietary affitome technology for the prevention of Alzheimer’s disease, Parkinson’s disease, atherosclerosis, multiple system atrophy, diabetes and other diseases. Its pipeline products comprise PCSK9; a-Syn PD01/PD03, PD04; Ab AD05, HTT and IgE. The company offers its technologies and services to the customers across Austria, Albania, Bosnia-Herzegovina, Canada, Croatia, Macedonia, Australia, Russia, Romania, Serbia, the US and Belarus. AFFiRiS is headquartered in Vienna, Austria.

AFFiRiS AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
AFFiRiS AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
AFFiRiS AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
AFFiRiS AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
AFFiRiS AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
AFFiRiS AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
AFFiRiS AG, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
AFFiRiS Raises USD11.4 Million in Venture Financing 10
AFFiRiS Secures US$34 Million In Venture Financing 11
Partnerships 12
AFFiRiS Enters Into Co-Development Agreement With Medical University Of Vienna 12
Licensing Agreements 13
AFFiRiS Extends Licensing Agreement With GlaxoSmithKline 13
Equity Offering 14
AFFiRiS Raises USD11.3 Million in Equity Financing 14
AFFiRiS AG – Key Competitors 15
AFFiRiS AG – Key Employees 16
AFFiRiS AG – Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
AFFiRiS AG, Pharmaceuticals & Healthcare, Key Facts 2
AFFiRiS AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
AFFiRiS AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
AFFiRiS AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
AFFiRiS AG, Deals By Therapy Area, 2011 to YTD 2017 8
AFFiRiS AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
AFFiRiS Raises USD11.4 Million in Venture Financing 10
AFFiRiS Secures US$34 Million In Venture Financing 11
AFFiRiS Enters Into Co-Development Agreement With Medical University Of Vienna 12
AFFiRiS Extends Licensing Agreement With GlaxoSmithKline 13
AFFiRiS Raises USD11.3 Million in Equity Financing 14
AFFiRiS AG, Key Competitors 15
AFFiRiS AG, Key Employees 16

★海外企業調査レポート[AFFiRiS AG-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bank Alfalah Ltd:企業の戦略・SWOT・財務情報
    Bank Alfalah Ltd - Strategy, SWOT and Corporate Finance Report Summary Bank Alfalah Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • QuadraMed Corp-医療機器分野:企業M&A・提携分析
    Summary Quadramed Corporation (Quadramed) is a healthcare technologies and service provider. It provides solutions to various healthcare organizations to improve the safety, efficiency and quality of patient care. The company's solutions enable its clients in streamlining processes, increase product …
  • Toleranzia AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Toleranzia AB (Toleranzia) is a drug developer that utilizes immune system’s intrinsic power to treat autoimmune diseases. The company offers products and technologies including Re-Tolerogen for the treatment of autoimmune diseases. Its Re-Tolerogen platform technology is a fusion protein fo …
  • Johnson Matthey Plc (JMAT):製薬・医療:M&Aディール及び事業提携情報
    Summary Johnson Matthey Plc (Johnson Matthey) is a specialty chemicals and sustainable technologies provider. It offers catalysts, fine chemicals, specialty chemical products and related technologies for various chemical processes and applications. It also undertakes the marketing, distribution, fab …
  • Nabors Industries Ltd (NBR):企業の財務・戦略的SWOT分析
    Nabors Industries Ltd (NBR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • The Vanguard Group, Inc.:企業の戦略・SWOT・財務情報
    The Vanguard Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Vanguard Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Innocoll AG:医療機器:M&Aディール及び事業提携情報
    Summary Innocoll AG (Innocoll), formerly Innocoll Holdings Plc is a pharmaceutical company that carries out the development and manufacturing of surgical implants and topically applied healthcare products in the areas of unmet clinical needs. The company’s pipeline product Xaracoll, a bupivacaine HC …
  • Media General, Inc.:企業のM&A・事業提携・投資動向
    Media General, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Media General, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Agilysys Inc (AGYS):企業の財務・戦略的SWOT分析
    Agilysys Inc (AGYS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Atkore International Group Inc. (ATKR):企業の財務・戦略的SWOT分析
    Atkore International Group Inc. (ATKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • SEAS-NVE Holding AS:企業の戦略的SWOT分析
    SEAS-NVE Holding AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Norsk Hydro ASA:企業の戦略・SWOT・財務情報
    Norsk Hydro ASA - Strategy, SWOT and Corporate Finance Report Summary Norsk Hydro ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • EllisDon Corporation:企業の戦略・SWOT・財務情報
    EllisDon Corporation - Strategy, SWOT and Corporate Finance Report Summary EllisDon Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • CoreSite Realty Corp (COR):企業の財務・戦略的SWOT分析
    CoreSite Realty Corp (COR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Checkpoint Therapeutics Inc (CKPT):製薬・医療:M&Aディール及び事業提携情報
    Summary Checkpoint Therapeutics Inc (Checkpoint Therapeutics), a subsidiary of Fortress Biotech Inc, is a clinical-stage biopharmaceutical company that acquires, develops and commercializes non-chemotherapy and immune enhanced combination treatments for the treatment of solid tumor cancers. The comp …
  • Dino Polska S.A (DNP):企業の財務・戦略的SWOT分析
    Dino Polska S.A (DNP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Telefonaktiebolaget LM Ericsson (ERIC B):企業の財務・戦略的SWOT分析
    Telefonaktiebolaget LM Ericsson (ERIC B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Bank of Maharashtra:企業の戦略・SWOT・財務情報
    Bank of Maharashtra - Strategy, SWOT and Corporate Finance Report Summary Bank of Maharashtra - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Posco Daewoo Corp (047050):企業の財務・戦略的SWOT分析
    Posco Daewoo Corp (047050) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Audentes Therapeutics Inc (BOLD):企業の財務・戦略的SWOT分析
    Summary Audentes Therapeutics Inc (Audentes) is a biotechnology company. It focuses on the development and commercialization of gene therapy products for rare diseases. The company’s pipeline products include AT132, intended for the treatment of X-linked myotubular myopathy; AT982, for the treatment …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆